What Celtaxsys does

Celtaxsys is a privately held, Atlanta-based biopharmaceutical company founded in 2004 that is described in firmographic data as engaged in developing and testing drug compounds for cancer. The therapeutic focus signaled by its later capital base is narrower and includes cystic fibrosis, evidenced by a $5,000,000 award from the Cystic Fibrosis Foundation in March 2019 — the most recent financing on record and a non-dilutive grant typical of foundation-backed translational programs rather than oncology venture rounds. Across its operating history the company raised an estimated $65 million in aggregate across seven disclosed financings between 2005 and 2019, with a peak Series 3 round of $45,000,000 in June 2015 led by Domain Associates and a repeat syndicate that included Lumira Ventures, Masters Capital Management, RMI Partners, GRA Venture Fund, and Georgia Research Alliance.

No commercial products, pricing model, partnerships, customers, or named drug candidates are disclosed in the available data set, and only one governance figure — Rick Eiswirth, Director and Audit Committee Chairman — is identified. Firmographic headcount is reported at 1-10 employees, a scale consistent with a small clinical-stage operation rather than a commercial-stage biopharma. The company's primary web domain, Celtaxsys.com, is currently listed for sale on HugeDomains for $3,595, indicating that the entity is no longer maintaining an active corporate web presence. No capital has been raised since March 2019, and there are no disclosed acquisitions, partnerships, product launches, regulatory milestones, or leadership changes subsequent to that date.

The business model implied by the data is grant- and equity-funded translational drug development, with no visible path to commercial revenue within the source material. For diligence purposes, the operating status of the legal entity, status of any drug-candidate IP, and the cause of the domain lapse (dormancy, wind-down, or reverse-acquisition by a successor entity) are material open questions not resolvable from the available sources.

Name

Celtaxsys

Website

https://celtaxsys.com

Company type

Private

Founded year

2004

Headcount range

1–10 employees

Short description

Celtaxsys is a private, Atlanta-based biopharmaceutical company founded in 2004 that developed and tested drug compounds for cancer and related indications, funded historically by life-sciences specialist VCs and the Cystic Fibrosis Foundation. No commercial products are disclosed and the company's web domain is currently listed for sale.

Ownership category

akta.pro rank

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Celtaxsys is a biopharmaceutical company engaged in developing and testing drug compounds for treating cancer. The company's research activity centers on oncology drug discovery and the testing of therapeutic compounds through pharmaceutical R&D processes.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Vertex Pharmaceuticals: Vertex is the dominant commercial-stage biopharma in cystic fibrosis and a natural reference for any CF-focused inflammation company. Celtaxsys's historical CFF funding and inflammation-mechanism focus place it in the same disease ecosystem, though Vertex operates at vastly greater scale.
• AbbVie: AbbVie is a major biopharma with inflammation franchises relevant to Celtaxsys's described drug development work. Relevant as an incumbent acquirer/partner for any oncology or inflammation assets.
• Pfizer: Pfizer is a broad oncology biopharma incumbent. Useful as a reference acquirer/partner for a small oncology-focused biotech such as Celtaxsys is described to be.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a major oncology biopharma incumbent. Comparable as a broad incumbent acquirer/partner for early-stage oncology programs.

Emerging players

• Translate Bio (acquired by Sanofi): Translate Bio developed mRNA therapeutics for cystic fibrosis prior to its acquisition. Like Celtaxsys, it was a clinical-stage private/small-cap biotech working in CF inflammation, making it a relevant comparable for program profile and investor base.
• ProQR Therapeutics: ProQR is a clinical-stage RNA therapeutics company focused on cystic fibrosis and rare genetic diseases. Comparable to Celtaxsys in stage, capitalization profile, and CF therapeutic focus.
• Eloxx Pharmaceuticals: Eloxx developed read-through agents for nonsense mutations, including cystic fibrosis. Small clinical-stage biotech with a comparable investor profile and disease focus.
• Corbus Pharmaceuticals: Corbus is a clinical-stage biopharma developing therapeutics for inflammatory and fibrotic diseases, including CF-related inflammation. Comparable in mechanism area (inflammation) and clinical-stage profile.
• Arcturus Therapeutics: Arcturus is a clinical-stage RNA medicines company that has had CF programs and operates in similar rare-disease inflammatory indications. Comparable stage and indication adjacency.
• Laurent Pharmaceuticals: Laurent Pharmaceuticals is a small clinical-stage Canadian biotech focused on inflammation in cystic fibrosis. A close comparable in therapeutic area, stage, and size.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celtaxsys